Company / Shareholders' Equity
Lucid Diagnostics Inc. Shareholders' Equity History
FY2021-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
-$2.3M
FY2024
5-year range
-$13.5M / $54.7M
FY2021-FY2024
Trend
-110.0%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Lucid Diagnostics Inc. reports negative total equity of -$2M in FY2024. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-$2M in FY2024.
Declined from $55M to -$2M over the past 2 years.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2024, shareholders' equity decreased 110.0% year-over-year.
Company context
Key Data Points
- Altman Z-Score -4.82 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$2.3M | -110.0% |
| FY2023 | $23.0M | -57.9% |
| FY2022 | $54.7M | +504.9% |
| FY2021 | -$13.5M | - |
As of FY2024 · SEC 10-K Annual Filings · Updated Jun 24, 2026